Health Care • Biotechnology: Pharmaceutical Preparations
$598.72 ▲ +5.18
(+0.87%)
MKT CAP: $25.68B • VOL: 518.6K
52W L $430 52W H $610
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$503
MEDIAN
$671
MEAN
$683
HIGH
$814
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE UTHR TAPE
UTHR // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $724.45 | $688.53 | 2025-02-14 | $544.84 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $754.39 | $706.49 | 2025-02-06 | $562.80 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $682.54 | $658.59 | 2025-01-29 | $574.77 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $610.69 | — | 2025-01-17 | $586.75 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $526.87 | $568.78 | 2025-01-09 | $532.86 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $712.48 | $622.67 | 2024-12-18 | $520.89 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $580.76 | $604.71 | 2024-12-04 | $556.81 | -4.3% | 48% | C |